{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:06:09Z","timestamp":1775945169971,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,8,3]],"date-time":"2009-08-03T00:00:00Z","timestamp":1249257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The Honduran HIV\/AIDS Program began to scale up access to HIV therapy in 2002. Up to May 2008, more than 6000 patients received combination antiretroviral therapy (cART). As HIV drug resistance is the major obstacle for effective treatment, the purpose of this study was to assess the prevalence of antiretroviral drug resistance in Honduran HIV\u20101\u2010infected individuals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We collected samples from 138 individuals (97 adults and 41 children) on cART with virological, immunological or clinical signs of treatment failure. HIV\u20101 <jats:italic>pol<\/jats:italic> sequences were obtained using an in\u2010house method. Resistance mutations were identified according to the 2007 International AIDS Society (IAS)\u2010USA list and predicted susceptibility to cART was scored using the <jats:sc>anrs<\/jats:sc> algorithm.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Resistance mutations were detected in 112 patients (81%), 74% in adults and 98% in children. Triple\u2010, dual\u2010 and single\u2010class drug resistance was documented in 27%, 43% and 11% of the study subjects, respectively. Multiple logistic regression showed that resistance was independently associated with type of treatment failure [virological failure (odds ratio (OR)=1) <jats:italic>vs<\/jats:italic>. immunological failure (OR=0.11; 95% confidence interval (CI) 0.030\u20130.43) <jats:italic>vs<\/jats:italic>. clinical failure (OR=0.037; 95% CI 0.0063\u20130.22)], route of transmission (OR=42.8; 95% CI 3.73\u2013491), and years on therapy (OR=1.81; 95% CI 1.11\u20132.93).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The prevalence of antiretroviral resistance was high in Honduran HIV\u2010infected patients with signs of treatment failure. A majority of study subjects showed dual\u2010 or triple\u2010class resistance to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors and protease inhibitors. Virologically defined treatment failure was a strong predictor of resistance, indicating that viral load testing is needed to correctly identify patients with treatment failure attributable to resistance.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00747.x","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T03:00:05Z","timestamp":1249354805000},"page":"95-103","source":"Crossref","is-referenced-by-count":33,"title":["Prevalence of drug resistance and importance of viral load measurements in Honduran HIV\u2010infected patients failing antiretroviral treatment"],"prefix":"10.1111","volume":"11","author":[{"given":"W","family":"Murillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"IL","family":"De Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Parham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Jovel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Palou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AC","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,1,4]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"22","article-title":"Decline in the AIDS and death rates in the EuroSIDA Study","volume":"362","author":"Mocroft A","year":"2003","journal-title":"an observational study"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_6_4_2","first-page":"827","article-title":"Treatment for adult HIV infection","volume":"14","author":"Hammer SM","year":"2006","journal-title":"2006 recommendations of the International AIDS Society\u2013USA Panel"},{"key":"e_1_2_6_5_2","first-page":"486","article-title":"Antiretroviral treatment of HIV infection","volume":"39","author":"Josephson F","year":"2007","journal-title":"Swedish recommendations 2007"},{"key":"e_1_2_6_6_2","unstructured":"WHO\/UNICEF.Towards universal access. Scaling up priority HIV\/AIDS interventions in the health sector. Progress Report. June 2008. Available athttp:\/\/www.unicef.org\/aids\/files\/towards_universal_access_report_2008.pdf(last accessed 27 July 2009)."},{"key":"e_1_2_6_7_2","unstructured":"UNGASS.2008UNGASS Country Progress Report. Available athttp:\/\/www.unaids.org\/en\/CountryResponses\/Countries\/honduras.asp2008."},{"key":"e_1_2_6_8_2","unstructured":"Reporte Nacional de VIH\/SIDA.Tegucigalpa Honduras Programa Nacional de ITS\/VIH\/SIDA 2007:1\u20132."},{"key":"e_1_2_6_9_2","first-page":"113","article-title":"Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1","volume":"37","author":"Hirsch MS","year":"2003","journal-title":"2003 recommendations of an International AIDS Society-USA Panel"},{"key":"e_1_2_6_10_2","first-page":"119","article-title":"Update of the drug resistance mutations in HIV\u20101","volume":"15","author":"Johnson VA","year":"2007","journal-title":"2007"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/432763"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000131310.52526.c7"},{"key":"e_1_2_6_13_2","first-page":"12","article-title":"Prevalence of HIV\u20101 drug resistance in treated patients","volume":"46","author":"Costagliola D","year":"2007","journal-title":"a French nationwide study"},{"key":"e_1_2_6_14_2","first-page":"605","article-title":"Validation of a simplified medication adherence questionnaire in a large cohort of HIV\u2010infected patients","volume":"16","author":"Knobel H","year":"2002","journal-title":"the GEEMA Study"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(02)00188-X"},{"key":"e_1_2_6_16_2","first-page":"1596","article-title":"MEGA4","volume":"24","author":"Tamura K","year":"2007","journal-title":"molecular evolutionary genetics analysis (MEGA) software version 4.0"},{"issue":"17","key":"e_1_2_6_17_2","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded survillance case definition for AIDS among adolescents and adults","volume":"41","author":"Centers for Disease Control (CDC).","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_6_18_2","unstructured":"ReynoldsS.Evaluation of the WHO Immunologic Criteria for ART Failure among Adults in Rakai Uganda.16th Conference on Retroviruses and Opportunistic Infections. Montreal Canada February 2009 [Abstract 144]."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830e4cd8"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318186eb18"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.12.5653"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.2.205"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.2.229"},{"key":"e_1_2_6_24_2","first-page":"1195","article-title":"Absence of zidovudine resistance in antiretroviral\u2010na\u00efve patients following zidovudine\/lamivudine\/protease inhibitor combination therapy","volume":"14","author":"Maguire M","year":"2000","journal-title":"virological evaluation of the AVANTI 2 and AVANTI 3 Studies"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200001280-00001"},{"key":"e_1_2_6_26_2","first-page":"3155","article-title":"Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1\u2010infected patients","volume":"44","author":"Joly V","year":"2000","journal-title":"evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M\/3331\/0013B Study Group"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.11.006"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.4.1760-1762.2003"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00779-07"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00747.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00747.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:11:51Z","timestamp":1698657111000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00747.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00747.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00747.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,4]]}}}